Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: A retrospective ecological study

Beck, Charles R.; Cloke, Rachel; O’Moore, Éamonn; Puleston, Richard

doi:10.1016/j.vaccine.2012.01.020

Cited by 15 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The methods used to investigate the vaccination status of the inmates were: serological testing ( n = 10) [ 20 , 21 , 23 , 24 , 25 , 35 , 42 , 44 , 45 , 46 ], the use of questionnaires ( n = 5) [ 28 , 33 , 37 , 38 , 40 ], the combination of both ( n = 3) [ 26 , 31 , 36 ], the screening of institutional databases ( n = 5) [ 27 , 29 , 30 , 32 , 34 ], or directly by conducting a survey ( n = 5) [ 19 , 22 , 39 , 41 , 43 ].…”

Section: Resultsmentioning

confidence: 99%

“…The aim of the studies was to evaluate systematic vaccination or relevant update of the adult vaccination program ( n = 21) [ 19 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ], to explore the coverage of risk groups ( n = 7) [ 20 , 23 , 36 , 42 , 43 , 44 , 45 ], including in some studies vaccination status at the time of admission to prison ( n = 6) [ 20 , 24 , 35 , 37 , 43 , 46 ]. The risk groups studied were IDUs and hepatitis C positive (HCV) in the HBV studies [ 23 , 42 , 43 , 44 , 45 ], and men who have sex with men in a combined HAV/HBV immunization study [ 19 ] and in another HAV immunization study [ 20 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination Coverage among Prisoners: A Systematic Review

Vicente-Alcalde¹,

Ruescas-Escolano

Harboe

et al. 2020

IJERPH

View full text Add to dashboard Cite

Prison inmates are highly susceptible for several infectious diseases, including vaccine-preventable diseases. We conducted a systematic international literature review on vaccination coverage against hepatitis B virus (HBV), hepatitis A virus (HAV), combined HAV/HBV, tetanus-diphtheria, influenza, pneumococcal, and combined measles, mumps, and rubella (MMR) in prison inmates, according to the PRISMA guidelines. The electronic databases were used Web of Science, MEDLINE, Scopus, and Cinhal. No language or time limit were applied to the search. We defined vaccination coverage as the proportion of vaccinated prisoners. There were no limitations in the search strategy regarding time period or language. Of 1079 identified studies, 28 studies were included in the review. In total, 21 reported on HBV vaccine coverage (range between 16–82%); three on HAV (range between 91–96%); two studies on combined HAV/HBV (77% in the second dose and 58% in the third); three studies on influenza vaccine (range between 36–46%), one of pneumococcal vaccine coverage (12%), and one on MMR coverage (74%). We found that data on vaccination coverage in prison inmates are scarce, heterogeneous, and do not include all relevant vaccines for this group. Current published literature indicate that prison inmates are under-immunized, particularly against HBV, influenza, MMR, and pneumococci. Strengthen immunization programs specifically for this population at risk and improvement of data record systems may contribute to better health care in prisoners.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Vaccination Coverage among Prisoners: A Systematic Review

Vicente-Alcalde¹,

Ruescas-Escolano

Harboe

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Scotland, England, and Wales have successfully established routine HBV vaccination programs in their correctional systems [32, 33]. Besides these studies, there is scant literature regarding the establishment of HBV vaccination programs for incarcerated individuals outside the United States.…”

Section: Access To Vaccinationmentioning

confidence: 99%

Epidemiology and Treatment of Hepatitis B in Prisoners

Smith

Uvin

Macmadu

et al. 2017

Curr Hepatology Rep

View full text Add to dashboard Cite

Purpose of Review The review details recent literature reports regarding Hepatitis B Virus (HBV) and, in particular, Hepatitis B prevalence/incidence in incarcerated populations around the world. Furthermore, the review will summarize the national/international guidelines regarding HBV and look at diagnosis, vaccination, treatment, and linkage to care after release. Recent Findings HBV affects prisoners at a much higher rate than the general populations. Many who are at increased risk for HBV infection are also at increased risk for incarceration. Incarcerated settings also have higher rates of HBV transmission. Summary Incarcerated individuals should be immunized if they are not already immune to HBV. Increased access to safe injecting and tattoo paraphernalia, condoms, and personal hygiene equipment could reduce the spread of HBV and other blood-borne and sexually transmitted infections. Future research should focus on ways to prevent the spread of HBV and similar viruses in incarcerated settings in order to protect incarcerated individuals and the general public. Research on effective linkage to community HBV care following release is needed.

show abstract

“…The unadjusted mortality rate in the general population by age was from UK life tables for England and Wales 28.…”

Section: Methodsmentioning

confidence: 99%

An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence

et al. 2016

View full text Add to dashboard Cite

AimsTo determine whether the provision of contingency management using financial incentives to improve hepatitis B vaccine completion in people who inject drugs entering community treatment represents a cost‐effective use of health‐care resources.DesignA probabilistic cost‐effectiveness analysis was conducted, using a decision‐tree to estimate the short‐term clinical and health‐care cost impact of the vaccination strategies, followed by a Markov process to evaluate the long‐term clinical consequences and costs associated with hepatitis B infection.Settings and participantsData on attendance to vaccination from a UK cluster randomized trial.InterventionTwo contingency management options were examined in the trial: fixed versus escalating schedule financial incentives.MeasurementLife‐time health‐care costs and quality‐adjusted life years discounted at 3.5% annually; incremental cost‐effectiveness ratios.FindingsThe resulting estimate for the incremental life‐time health‐care cost of the contingency management strategy versus usual care was £21.86 [95% confidence interval (CI) = –£12.20 to 39.86] per person offered the incentive. For 1000 people offered the incentive, the incremental reduction in numbers of hepatitis B infections avoided over their lifetime was estimated at 19 (95% CI = 8–30). The probabilistic incremental cost per quality adjusted life‐year gained of the contingency management programme was estimated to be £6738 (95% CI = £6297–7172), with an 89% probability of being considered cost‐effective at a threshold of £20 000 per quality‐adjusted life years gained (97.60% at £30 000).ConclusionsUsing financial incentives to increase hepatitis B vaccination completion in people who inject drugs could be a cost‐effective use of health‐care resources in the UK as long as the incidence remains above 1.2%.

show abstract

Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: A retrospective ecological study

Cited by 15 publications

References 6 publications

Vaccination Coverage among Prisoners: A Systematic Review

Vaccination Coverage among Prisoners: A Systematic Review

Epidemiology and Treatment of Hepatitis B in Prisoners

An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence

Contact Info

Product

Resources

About